Pharmaceutical Decision and Game Theory

  • Mark Chang
Part of the Statistics for Biology and Health book series (SBH)


A pharmaceutical or biopharmaceutical company is a commercial business licensed to research, develop, market, and/or distribute drugs, most commonly in the context of healthcare. It is subject to a variety of laws and regulations regarding the patenting, testing, and marketing of drugs, particularly prescription drugs.


Nash Equilibrium Cooperative Game Markov Decision Process Noncooperative Game Compulsory License 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Readings and References

  1. Barfield, C.E., Groombridge, M.A.: The economic case for copyright and owner control over parallel imports. J. World Intellect. Prop. 1, 903–939 (1998)CrossRefGoogle Scholar
  2. Bellman, R.: A Markovian decision process. J. Math. Mech. 6, 23–35 (1957a)Google Scholar
  3. Bellman, R.: Dynamic Programming. Princeton University Press, Princeton (1957b)zbMATHGoogle Scholar
  4. Berger, J.: Statistical Decision Theory and Bayesian Analysis. Springer, New York (1985)zbMATHGoogle Scholar
  5. Bernard, S.: The drug drought, Pharmaceutical Executive, November 1 (2002). Accessed 15 June 2010
  6. Bertsekas, D.: Dynamic Programming and Optimal Control, vol. 2. Athena, Belmont (1995)zbMATHGoogle Scholar
  7. Braess, D.: Über ein Paradoxon aus der Verkehrsplanung. Unternehmensforschung 12, 258–268 (1969)CrossRefMathSciNetGoogle Scholar
  8. Cambridge Pharma Consultancy: Pricing and Reimbursement Review 2003. IMS Health-Management Consulting, Cambridge (2004)Google Scholar
  9. Chang, M.: Biomarker development. In: Statistics for Translational Medicine. Taylor and Francis, New York (2008)Google Scholar
  10. Chang, M., Chow, S.C.: Power and sample size for dose response studies. In: Ting, N. (ed.) Dose Finding in Drug Development. Springer, New York (2006)Google Scholar
  11. Chang, M.: Monte Carlo Simulation for the Pharmaceutical Industry. Chapman and Hall/CRC, Boca Raton (2010)CrossRefGoogle Scholar
  12. Chard, J.S., Mellor, C.J.: Intellectual property rights and parallel imports. World Econ. 12, 69–83 (1989)CrossRefGoogle Scholar
  13. Danzon, P., Towse, A.: Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. Int. J. Health Care Finance Econ. 3, 183–205 (2003)CrossRefGoogle Scholar
  14. Gosavi, A.: Simulation-based Optimization: Parametric Optimization Techniques and Reinforcement Learning. Springer, Boston (2003)zbMATHGoogle Scholar
  15. Dresher, M.: Games of Strategy. Prentice-Hall, Englewood Cliffs (1961)zbMATHGoogle Scholar
  16. Grossman, G., Lai, E.: Parallel imports and price controls. RAND J Econ. 39(2), 378–402 (2008)CrossRefGoogle Scholar
  17. Havil, J.: Impossible? Surprising Solutions to Counterintuitive Conundrums. Princeton University Press, Priceton (2008)Google Scholar
  18. Hu, M., Schultz, K., Sheu, J., Tschopp, D.: The Innovation Gap in Pharmaceutical Drug Discovery & New Models for R&D Success. (2007). Accessed 2 Mar 2009
  19. McCain, R.: Strategy and Conflict: An Introductory Sketch of Game Theory. (2009). Accessed 20 June 2009
  20. Nash, J.: Non-coorperative games. Ann. Math. 5, 286–295 (1951)MathSciNetGoogle Scholar
  21. Parmigiani, G., Inoue, L.: Decision Theory: Principles and Approaches. Wiley, Hokoken (2009)zbMATHCrossRefGoogle Scholar
  22. Pearlman, J.B.: The commercialization of medicine. (2007). Accessed 10 Sep 2009
  23. Powell, W.B.: Approximate Dynamic Programming: Solving the Curses of Dimensionality. Wiley-Interscience, New York (2007)zbMATHCrossRefGoogle Scholar
  24. Watson, J.: Strategy. W.W. Norton and Company, New York (2008)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Mark Chang
    • 1
  1. 1.BiometricsAMAG Pharmaceuticals, Inc.LexingtonUSA

Personalised recommendations